Windlas Biotech Limited
ListedMainboardHealthcare & Pharmaceuticals · NSE / BSE
Incorporated in 2001, Windlas Biotech Ltd is a prominent pharmaceutical company in India’s CDMO segment, offering end-to-end services from product discovery and development to licensing and commercial manufacturing of generic and complex generic products. The company also markets its own branded products in the trade generics and OTC segments, focusing on chronic therapeutic categories related to lifestyle disorders. Windlas Biotech operates across three verticals: CDMO services, domestic trade generics and nutraceuticals, and exports. Its marquee clients include Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals, and Systopic Laboratories. The company’s Dehradun-based manufacturing facilities have an installed capacity of 7,063.83 million tablets/capsules, 54.46 million pouches/sachets, and 61.08 million liquid bottles.
Price Band
₹448 – ₹460
Issue Size
₹402 Cr
Lot Size
30 shares
GMP
₹80
+17.4%
Est. Listing
₹540
at current GMP
Subscribed
—
Open
4 Aug 2021
Close
6 Aug 2021
Allotment
11 Aug 2021
Refund
12 Aug 2021
Demat Credit
13 Aug 2021
Listing
16 Aug 2021
Last updated 12 days ago
Live Grey Market Premium
Windlas Biotech Limited GMP Today
Last updated: 19 Oct 2026
Current Premium
₹80+17.4%
Issue Price (Upper)
₹460
Band: ₹448 – ₹460
Estimated Listing Price
₹540
Upper price + GMP
Lot Size
30 shares
Min investment ₹13,800
Estimated Profit / Lot
₹2,400
30 × ₹80
Windlas Biotech Limited GMP Historical Trend
GMP History
Grey Market Premium trend
+₹80
▲ 0 today
Updated 1 minute ago
Estimated Listing Price
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 31 Oct 2026 | +₹80 | 17.4% | ₹540 |
| 30 Oct 2026 | +₹80 | 17.4% | ₹540 |
| 29 Oct 2026 | +₹72 | 15.7% | ₹532 |
GMP is unofficial market data. Not a guarantee of listing performance.
About Windlas Biotech Limited Public Issue & Market Profile
Windlas Biotech Limited is bringing an initial public offering (IPO) in the Healthcare & Pharmaceuticals sector with an aggregate issue size of ₹402 Crores. The shares are offered at a price band of ₹448 to ₹460 per equity share on NSE and BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
Public Issue & Pricing Context:
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Basis of Allotment & Listing Timeline:
Following the close of bidding on 2021-08-06, the basis of allotment is scheduled to be finalized on 2021-08-11. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Link Intime India Private Limited) or the BSE allotment checking window.
Frequently Asked Questions
What is Windlas Biotech Limited IPO GMP today?
The latest grey market premium for Windlas Biotech Limited IPO is ₹80, which indicates an expected listing price of ₹540.
What does Kostak Rate and Sauda mean in IPO GMP?
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
Is Grey Market Premium officially recognized?
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.